117519-09-2

Basic information

• Product Name: 3-Amino-2-chloro-6-(trifluoromethyl)pyridine
• Synonyms: 2-CHLORO-6-(TRIFLUOROMETHYL)PYRIDIN-3-AMINE;3-AMINO-2-CHLORO-6-(TRIFLUOROMETHYL)PYRIDINE;2-chloro-3-amino-6-(trifluoromethyl) pyridine;2-Chloro-6-(trifluoromethyl)-3-pyridylamine;3-AMINO-2-CHLORO-6-(TRIFLUOROMETHYL)PYRIDINE, 97% MIN.;N,N'-bis(benzyl)oxamide;N,N'-bis(phenylmethyl)ethanediamide;N,N'-bis(phenylmethyl)oxamide
• CAS NO: 117519-09-2
• Molecular Formula: C₆H₄ClF₃N₂
• Molecular Weight: 196.56
• EINECS: 1312995-182-4
• Product Categories: Amines and Anilines;Heterocycles;pharmacetical;Amines;Pyridines;Pyridine;Pyridine series;Fluorine series
• Mol File: 117519-09-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 92-94°C
• Boiling Point: 231.8 °C at 760 mmHg
• Flash Point: 94 °C
• Appearance: White to light yellow crystal powder
• Density: 1.507 g/cm³
• Vapor Pressure: 0.0612mmHg at 25°C
• Refractive Index: 1.501
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -1.20±0.10(Predicted)
• CAS DataBase Reference: 3-Amino-2-chloro-6-(trifluoromethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-2-chloro-6-(trifluoromethyl)pyridine(117519-09-2)
• EPA Substance Registry System: 3-Amino-2-chloro-6-(trifluoromethyl)pyridine(117519-09-2)

Safety Data

• Hazard Codes: Harmful:
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: Cool,dry,tightly closed
• Hazardous Substances Data: 117519-09-2(Hazardous Substances Data)

Usage

Chemical Properties

White to light yellow crystal powder

InChI:InChI=1/C6H4ClF3N2/c7-5-3(11)1-2-4(12-5)6(8,9)10/h1-2H,11H2

Upstream product

• 386704-05-8 2-chloro-6-(trifluoromethyl)nicotinamide 
• 106877-33-2 6-(trifluoromethyl)pyridin-3-amine 

Downstream Products

• 1196697-64-9 2-chloro-N-{1'-[(E)-3-(4-chloro-phenyl)-allyl]-6-trifluoromethyl-1',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl-3-yl}-isonicotinamide 2-ethyl-hexanoic acid salt 
• 1196844-72-0 2-chloro-N-{1'-[(E)-3-(4-chloro-phenyl)-allyl]-6-trifluoromethyl-1',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl-3-yl}-isonicotinamide N-oxide 
• 1196696-57-7 2-chloro-N-{1'-[(E)-3-(4-chloro-phenyl)-allyl]-6-trifluoromethyl-1',2',3',4',5',6'-hexahydro-[2,4']bipyridinyl-3-yl}-isonicotinamide 
• 1355342-87-8 2-chloro-N-[2-[[1-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-3-azetidinyl]oxy]-6-(trifluoromethyl)-3-pyridinyl]-4-pyridinecarboxamide 
• 1314530-59-0 N-[4-(tert-butylcarbamoyl-methyl)-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl]-3-chloro-benzamide 
• 1314531-21-9 (3'-amino-6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-acetic acid ethyl ester 
• 1303439-05-5 5-amino-1-(3-(pyrrolidin-1-ylmethyl)benzyl)-7-(trifluoromethyl)pyrido[4,3-b]pyrazine-2,3(1H,4H)-dione 
• 1303439-07-7 5-chloro-1-(3-(pyrrolidin-1-ylmethyl)benzyl)-7-(trifluoromethyl)pyrido[4,3-b]pyrazine-2,3(1H,4H)-dione 
• 1303439-06-6 2-chloro-N₄-(3-(pyrrolidin-1-ylmethyl)benzyl)-6-(trifluoromethyl)pyridine-3,4-diamine 
• 1181079-95-7 3-(2-chloro-6-trifluoromethylpyridin-3-yl)-5,5-dimethyl-1-(2-phenoxybenzyl)imidazolidine-2,4-dione 
• 89719-90-4 2,3-dichloro-6-(trifluoromethyl)pyridine 
• 1024010-48-7 2-(benzyloxy)-N-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)benzamide 
• 947146-74-9 4-bromo-2-chloro-6-(trifluoromethyl)pyridin-3-amine 
• 117519-08-1 2-chloro-3-nitro-6-(trifluoromethyl)pyridine 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS AS TLR-7 ACTIVITY MODULATORS

The invention provides compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

NOVEL PHARMACEUTICALS

The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.